Professor Zou Dajin: Principles of Prevention and Treatment of Common "Adverse Reactions" of SGLT2i

This article is published with the authorization of Professor Zou Dajin, please do not reprint without permission
.

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a rising star in the field of diabetes treatment in recent years.
It can also bring cardio-renal benefits
.

Based on the accumulation of rich evidence-based medical evidence and clinical practice experience, the recommendation status of SGLT2i in domestic and foreign guidelines/consensus has been continuously improved in recent years
.

With the increasing number of clinical applications, the safety of SGLT2i clinical medication has attracted much attention, such as "What are the common adverse reactions of SGLT2i, and how to prevent and deal with them?", "Is there some misunderstandings about the safety of SGLT2i?"
.

Recently, Yimaitong has the honor to invite Professor Zou Dajin to live online to answer your questions.
The core content is organized as follows
.

(